Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome.

[1] It is also under development for the treatment of solid tumors and alcoholism.

[1][2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor.

[1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.

This hormonal preparation article is a stub.